Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-498Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-70Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:498Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-636Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-94Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:636Price:$3.03
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-469Price:$3.60
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-68Price:$3.60
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:469Price:$3.60
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-625Price:$3.60
Filings by filing date
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-498Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-70Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:498Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-636Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-94Price:$3.03
-
Feb 02, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:636Price:$3.03
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-469Price:$3.60
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-68Price:$3.60
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Higgins Thomas TOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:469Price:$3.60
-
Jan 01, 2024 (filed on Mar 06, 2024)Insider Name:Gozani ShaiOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-625Price:$3.60
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1000 Winter Street WALTHAM MA 02451 |
Tel: | N/A |
Website: | https://www.neurometrix.com |
IR: | See website |
Key People | ||
Shai N. Gozani Chairman of the Board, President, Chief Executive Officer, Secretary | Thomas T. Higgins Chief Financial Officer, Senior Vice President, Treasurer |
Business Overview |
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud. |
Financial Overview |
For the fiscal year ended 31 December 2023, Neurometrix Inc revenues decreased 29% to $5.9M. Net loss increased 48% to $6.5M. Revenues reflect United States segment decrease of 34% to $4.7M. Higher net loss reflects General and administrative increase of 13% to $5M (expense), Sales and marketing increase of 17% to $3.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.96 to -$6.27. |
Employees: | 26 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $5.90M as of Dec 31, 2023 |
EBITDA (TTM): | -$7.10M as of Dec 31, 2023 |
Net annual income (TTM): | -$6.53M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.27M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,986,540 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |